Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
BCMA, CAR-T, CD19

Update on CBMG’s CAR-T Program; Q1 Investor Call

Here is a brief preview of this blast: On Wednesday, May 6, Cellular Biomedicine Group (CBMG) held their Q1 2020 earnings call (press release). The company announced the successful IND application for their BCMA CAR-T (C-CAR088) in China as well as positive data from the ongoing investigator-initiated trial. Management also expressed optimism about the early data from their bi-specific CD19/CD20 CAR-T in DLBCL. Below, FENIX provides further highlights from the call and thoughts around how CBMG’s CAR-Ts could potentially differentiate themselves, despite their early stage of development, in the CAR-T space currently led by much larger players such as Novartis, Gilead, and BMS.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.